Interaksjoner mellom metoprolol og antidepressive legemidler

Tidsskrift for den Norske Laegeforening

Volumn 131, Issue 18, 2011, Pages 1777-1779

  Molden, Espen ^a,b   Spigset, Olav ^c,d  

^a UNIVERSITY OF OSLO   (Norway)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; FLUOXETINE; METOPROLOL; PAROXETINE;

DRUG ANTAGONISM; DRUG COMBINATION; DRUG INTERACTION; HUMAN; REVIEW; RISK FACTOR;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FLUOXETINE; HUMANS; METOPROLOL; PAROXETINE; RISK FACTORS;

EID: 80155193813     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.11.0143     Document Type: Article

References (14)

1. Reseptregisteret. www.reseptregisteret.no (28.3.2011).
2. Wuttke H, Rau T, Heide R et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72: 429-37.
3. Bijl MJ, Visser LE, van Schaik RH et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in betablocker users. Clin Pharmacol Ther 2009; 85: 45-50.
4. Hemeryck A, Lefebvre RA, De Vriendt C et al. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 2000; 67: 283-91.
5. Goryachkina K, Burbello A, Boldueva S et al. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 2008; 64: 275-82.
6. Stout SM, Nielsen J, Welage LS et al. Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. J Clin Pharmacol 2011; 51: 389-96.
7. König F, Häfele M, Hauger B et al. Bradycardia after beginning therapy with metoprolol and paroxetine. Psychiatr Prax 1996; 23: 244-5.
8. Onalan O, Cumurcu BE, Bekar L. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clin Proc 2008; 83: 595-9.
9. Walley T, Pirmohamed M, Proudlove C et al. Interaction of metoprolol and fluoxetine. Lancet 1993; 341: 967-8.
10. McCollum DL, Greene JL, McGuire DK. Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol. Cardiovasc Drugs Ther 2004; 18: 329-30.
11. Preskorn SH, Greenblatt DJ, Flockhart D et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007; 27: 28-34.
12. Amchin J, Ereshefsky L, Zarycranski W et al. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol 2001; 41: 443-51.
13. Güzey C, Norström Å, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 2002; 24: 436-7.
14. Remeron SPC. www.legemiddelverket.no (28.3.2011).